Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ChAd-MVA 5T4 vaccine plus nivolumab in prostate cancer
2017-001992-22Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in prostate cancer (PCa) (2 arms), sponsored by University of Oxford. Primary endpoint: Safety (adverse events up to 12 months). Status: unknown.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-001992-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001992-22.